The promyelocytic leukemia protein (PML) is essential to sustain clear cell renal cell carcinoma (ccRCC) expansion via p53 inhibition and the PML-targeting drug arsenic trioxide exerts cancer inhibitory functions in ccRCC. The gene discussed is PML; the disease is clear cell renal carcinoma.